PFE - Bristol Myers Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study | Benzinga
Bristol Myers Squibb & Co (NYSE:BMY) and Exelixis Inc (NASDAQ:EXEL) revealed four-year follow-up results from a cancer study that compared one treatment with another from Pfizer Inc (NYSE:PFE).
What Happened: The Bristol Myers-Exelixis CheckMate -9ER trial evaluating Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) was held up against Pfizer’s Sutent (sunitinib) for previously untreated advanced or metastatic renal cell carcinoma (RCC).
At a median follow-up of 55.6 months, all patients randomized to the Opdivo plus Cabometyx treatment arm (n=323) continued to experience benefits over those who received sunitinib (n=328) across efficacy endpoints:
- Progression-free survival (PFS) continued to favor Opdivo plus Cabometyx, with median PFS nearly doubled with the combination regimen at 16.4 months vs. 8.4 months with sunitinib.
- Treatment with Opdivo in combination with Cabometyx elicited durable survival benefit over sunitinib, with a median overall survival (OS) of 46.5 months compared to 36.0 months ...